Bioequivalence and Safety of Twice‐Daily Sustained‐Release Paracetamol (Acetaminophen) Compared With 3‐ and 4‐Times‐Daily Paracetamol: A Repeat‐Dose, Crossover Pharmacokinetic Study in Healthy Volunteers. Issue 1 (16th August 2017)

• Record Type: Journal Article
• Authors: Liu, Dongzhou J.; Collaku, Agron
• Is Part Of: Clinical pharmacology in drug development. Volume 7:Issue 1(2018)
• Page Start: 77
• Page End: 86
• Publication Date: 2017-08-16
• Subjects: paracetamol -- acetaminophen -- bioequivalence -- steady state -- sustained release -- twice daily; Drugs -- Testing -- Periodicals; Drug development -- Periodicals; Clinical pharmacology -- Periodicals; 615.580724
• DOI: 10.1002/cpdd.369
• Languages: English
• ISSNs: 2160-7648

Abstract

Abstract: Twice‐daily sustained‐release (SR) paracetamol (acetaminophen) offers convenient administration to chronic users. This study investigated at steady state (during the last 24 hours of a 3‐day dosing period) the pharmacokinetics, bioequivalence, and safety of twice‐daily SR paracetamol compared with extended‐release (ER) and immediate‐release (IR) paracetamol. In this open‐label, randomized, multidose, 3‐way crossover study, 28 healthy subjects received paracetamol SR (2 × 1000 mg twice daily), ER (2 × 665 mg 3 times daily), and IR (2 × 500 mg 4 times daily). At steady state, twice‐daily SR paracetamol was bioequivalent to ER and IR paracetamol. The 90% confidence intervals for the ratios of geometric means were within the acceptance interval for SR/ER paracetamol (AUC0–t, 0.973–1.033; AUC0–24, 0.974–1.034; AUC0–∞, 0.948–1.011; Cmax, 1.082–1.212; Cav, 1.011–1.106) and SR/IR paracetamol (AUC0–t, 0.969–1.029; AUC0–24, 0.968–1.027; AUC0–∞, 0.963–1.026; Cmax, 0.902–1.010; Cav, 1.004–1.098). Given twice daily, the SR formulation demonstrated SR properties as expected. Mean time at or above a 4 μg/mL plasma concentration of paracetamol from 2 daily doses of the SR formulation was significantly longer than that from 4 daily doses of IR paracetamol. SR formulation also had a greater Tmax, a longer half‐life, and lower Cmin compared with ER and IR paracetamol. All formulations were well tolerated.